Keyphrases
Treatment Strategy
100%
Current Treatment
100%
Diagnosis Treatment
100%
Disease Risk Factors
100%
Factor Diagnosis
100%
Post-transplant Lymphoproliferative Disorder
100%
Immunosuppression
28%
Downstream Signaling
14%
Novel Treatments
14%
Risk Factors
14%
Viral Infection
14%
B Cells
14%
World Health Organization
14%
Central Nervous System
14%
Signaling Pathway
14%
Nervous System Diseases
14%
Diagnostic Categories
14%
Host Genetics
14%
Targeted Therapeutics
14%
Rituximab
14%
Combination Chemotherapy
14%
Disease Case
14%
Central Nervous System Tumors
14%
Allograft
14%
Latent Membrane Protein 1 (LMP1)
14%
Hodgkin Lymphoma
14%
CD30
14%
Recipient Age
14%
Adoptive Immunotherapy
14%
Solid Organ Transplantation
14%
Extranodal Disease
14%
Early Lesions
14%
Aggressive Lymphoma
14%
Hematopoietic Transplantation
14%
System Paradigm
14%
Degree of Infection
14%
EBV-negative
14%
Lymphoid Disorders
14%
NK-cell Lymphoma
14%
Immunology and Microbiology
Central Nervous System
100%
Immunosuppression
66%
Viral Disease
33%
B Cell
33%
Genetic Variation
33%
Natural Killer T Cell
33%
Rituximab
33%
Adoptive Immunotherapy
33%
Epstein Barr Virus
33%
Allograft
33%
Medicine and Dentistry
Posttransplant Lymphoproliferative Disease
100%
Immunosuppressive Treatment
28%
Central Nervous System
28%
B Cell
14%
Diagnosis
14%
Virus Infection
14%
Membrane Protein
14%
Allograft
14%
Central Nervous System Disease
14%
Hodgkin's Lymphoma
14%
Combination Chemotherapy
14%
Rituximab
14%
Genetic Variation
14%
Cell Signaling Pathway
14%
Epstein Barr Virus
14%
NK T Cell Lymphoma
14%
Adoptive Immunotherapy
14%
Aggressive Lymphoma
14%
Disease
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Posttransplant Lymphoproliferative Disease
100%
Chemotherapy
14%
Virus Infection
14%
Immunotherapy
14%
Membrane Protein
14%
Central Nervous System Disease
14%
Rituximab
14%
Hodgkin Disease
14%
NK T Cell Lymphoma
14%
Diseases
14%